Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 103 clinical trials
Featured trial
Heart Valve Disease – Aortic and Mitral

months, 1 year, 18 months, and annually through 10 years. Randomly assigned (50% to either group) Treatment of Aortic Stenosis with either Transcatheter Aortic Valve Replacement (TAVR) device or

stenosis
aortic valve replacement
  • 811 views
  • 05 Feb, 2021
  • 1 location
Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population

The purpose of this study is to evaluate the safety and effectiveness of transcatheter aortic valve replacement in Chinese population.

  • 0 views
  • 21 Jul, 2021
  • 1 location
Balloon vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis (BASELINE)

Transcatheter aortic valve implantation (TAVI) serves a growing spectrum of patients with symptomatic severe aortic stenosis (AS). Approximately 80% of surgical aortic valve replacements is

transcatheter aortic valve implantation
aortic valve replacement
regurgitation
stenosis
tavi
  • 1 views
  • 04 Oct, 2022
  • 4 locations
Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high …

  • 129 views
  • 20 Oct, 2022
  • 19 locations
Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden (Reduce-MFA)

The aim of the study is to evaluate the effect of antifibrotic therapy on regression of myocardial fibrosis after TAVI in patients with baseline high fibrotic burden. Therefore, patients will be treated with Spironolactone in addition to standard of care, Spioronolactone + Dihydralazine in addition to standard of care or …

  • 0 views
  • 12 Jul, 2022
  • 1 location
Transcatheter Aortic Valve Replacement For Patients With Bicuspid Aortic Stenosis (Type 0) Using Down Sizing Strategy Compared With Standard Sizing Strategy (HANGZHOU Solution): A Prospective, Multicenter, Randomized Controlled Trial (TAILOR-TAVR)

To compare down sizing strategy versus annular sizing strategy technique (control group) in Type 0 bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR

  • 0 views
  • 17 Oct, 2022
  • 1 location
Quantification of Debris Captured Using TCEP During VIV TAVR With BVF

transcatheter aortic valve replacement (VIV TAVR) with bioprosthetic valvular fracture (BVF)

  • 0 views
  • 18 Apr, 2022
  • 1 location
The ShortCut™ Study Protocol

leaflets in patients who are presented for a valve-in-valve transcatheter aortic valve replacement (TAVR) procedure, and who are at risk for TAVR-induced coronary artery ostium obstruction.

  • 0 views
  • 04 Oct, 2022
  • 1 location
Sedation or General Anesthesia During TAVR (ANESTAVI)

Transcatheter aortic valve replacement TAVR is become the reference method for patients with severe aortic stenosis who are contraindicated or at risk for surgical aortic replacement. Initially

  • 0 views
  • 23 Mar, 2022
  • 2 locations
  • 0 views
  • 04 Oct, 2022
  • 1 location